

September 24, 2018

# CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October

NEWARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the 2018 Cantor Global Healthcare Conference, the LEERINK Partners Roundtable Series: Rare Disease & Oncology, and the ROTH Battle of the NASH Thrones Investor Conference.

## **2018 Cantor Global Healthcare Conference**

Date: Monday, October 1  
Time: 8:55am Eastern Time  
Location: Intercontinental Barclay New York Hotel  
Webcast: <http://ir.cymabay.com/events>

## **LEERINK Partners Roundtable Series: Rare Disease & Oncology**

Date: Tuesday, October 2  
Time: 8:30am Eastern Time  
Location: Lotte New York Palace Hotel  
Webcast: <http://ir.cymabay.com/events>

## **ROTH Battle of the NASH Thrones Investor Conference**

Date: Wednesday, October 17  
Time: Panel discussions and 1-on-1 meetings  
Location: Park Hyatt New York Hotel

## **About CymaBay**

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR $\delta$  agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).

For additional information about CymaBay visit [www.cymabay.com](http://www.cymabay.com).

## **Contact:**

Hans Vitzthum  
LifeSci Advisors, LLC  
212-915-2568  
[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)



Source: CymaBay Therapeutics, Inc.